Encourage development of new antimicrobial... Antimicrobial resistance (AMR) is a global threat, particularly given the modest activity in the pipeline of new antimicrobials in development, and emerging resistance to existing antibiotics. In 2016, … more ➔
Serialisation using labelsAccording to the FMD 2011/62, serialisation of all prescription drug packs in Europe will inevitably become a daily routine for the pharmaceutical industry from 2019. European Biotechnology spoke with … more ➔
A unique approach to bring open innovation...In February, Johnson & Johnson Innovation, JLABS opened its first European open innovation incubator, JLABs @ BE, at the heart of the Beerse Janssen R&D Campus in Belgium. European Biotechnology … more ➔
Diversifying into oncology if ROI on bugs...Big Pharma’s interest in R&D on anti-infectives declined when other areas like oncology began offering higher returns. A few biotechs mirror pharma (Basilea, Idorsia and Polyphor), but could stay … more ➔
Formulation mattersBack in February 2017, CDMO Rentschler Biopharma SE and formulation specialist Leukocare AG joined forces to give biologics and biosimilar makers a competitive edge through significantly stabilised end … more ➔
Turning cancer into a chronic diseaseFollowing last year’s approval by the US FDA, the EU’s EMA has now also approved the first two T-cell-based immunotherapies against certain types of cancer. This marks the ultimate proof-of-concept … more ➔
Skilful asset swapping in the time of big...Independent investment analyst, Managing Director EQUI.TS GmbH_ Big data analytics is poised to change the way business is done in the life sciences. A string of recent M&A transactions illustrate … more ➔
Single-use plastics: New EU rules to reduc... Plastics are magical materials, and they will be even more important in the future than they are today. But they lead to microplastics in the environment, especially noticeable as marine littering. … more ➔
Balancing generic and innovative medical u...Is cheaper always better when it comes to generics? What about when it comes to innovative medical uses of them? more ➔
